Breast cancer diagnosed during or shortly after pregnancy is one of oncology's most vexing challenges — aggressive, understudied, and affecting women at the peak of reproductive life. A new molecular profiling study suggests that the specific physiological stage at diagnosis is not merely a timing detail but a fundamental determinant of tumor biology, with breastfeeding appearing to create a distinct immune environment that could be therapeutically exploited.
Using NanoString BC360 gene expression panels combined with CIBERSORTx computational immune deconvolution, investigators analyzed 106 breast cancer cases — 57 classified as pregnancy-associated breast cancer (PABC) and 49 non-PABC controls. Within the PABC cohort, cases were stratified by reproductive stage: gestation, active breastfeeding, or post-weaning. All PABC cases shared a core aggressive signature featuring heightened tumor proliferation and compromised DNA repair pathways. However, breastfeeding-diagnosed patients (PABC-BF) displayed a strikingly distinct immune phenotype: elevated inflammatory chemokine expression, enriched infiltration of both cytotoxic CD8⁺ T-cells and immunosuppressive regulatory T-cells, and prominent upregulation of the TIGIT inhibitory checkpoint.
The TIGIT finding is particularly noteworthy given the current wave of clinical interest in TIGIT-blocking immunotherapies, several of which are already in Phase II/III trials for other breast cancer subtypes. Lactation is known to trigger profound systemic immune remodeling — including immunotolerance mechanisms that normally protect breast tissue during milk production — and this study suggests those same pathways may be co-opted within the tumor microenvironment. The result is a paradox of inflammation and suppression coexisting, a pattern increasingly recognized in immunotherapy-responsive cancers. Limitations are significant: the cohort of 57 PABC patients is small, the analysis is retrospective and observational, and causal directionality between lactation physiology and immune infiltration cannot yet be established. Still, this work offers a credible biological rationale for staging-stratified immunotherapy trials in PABC — an incremental but genuinely directional finding for a historically underserved patient population.